CHINA RESOURCES BOYA BIO-PHARMACEUTICAL GROUP CO.,LTD

China Resources Boya Bio-pharmaceutical Group Co.,Ltd

300294

CNE100001FF1

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-05-19 pm EDT			5-day change	1st Jan Change
33.73 ^CNY	-1.32%		-2.29%	+0.15%

Apr. 23	China Resources Boya Bio-pharmaceutical Group Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 15	China Resources Boya Bio-Pharmaceutical Group Co.,Ltd. Approves Cash Dividend for the Year 2023	CI

China Resources Boya Bio-Pharmaceutical Group Co.,Ltd. Approves Cash Dividend for the Year 2023

April 15, 2024 at 03:39 pm EDT

China Resources Boya Bio-pharmaceutical Group Co.,Ltd. approved cash dividend/10 shares (tax included) of CNY 3.00000000 for the year 2023.

Latest news about China Resources Boya Bio-pharmaceutical Group Co.,Ltd

China Resources Boya Bio-pharmaceutical Group Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 23	CI
China Resources Boya Bio-Pharmaceutical Group Co.,Ltd. Approves Cash Dividend for the Year 2023	Apr. 15	CI
China Resources Boya Bio-Pharmaceutical Group Co.,Ltd Proposes Cash Dividend	Mar. 24	CI
CR Boya Bio-Pharmaceutical's 2023 Profit Falls on Lower Revenue	Mar. 14	MT
China Resources Boya Bio-pharmaceutical Group Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13	CI
CR Boya Bio-Pharmaceutical Signs 29.5 Million Yuan Construction Contract for Blood Products Facility	Feb. 06	MT
China Resources Double-Crane Pharmaceutical Co.,Ltd. completed the acqyusution 89.681% stake in Guizhou Tianan Pharmaceutical Company from Jiangxi Boya Pharmaceutical Investment Co., Ltd and China Resources Boya Bio-pharmaceutical Group Co.,Ltd.	Nov. 02	CI
CR Boya Bio-Pharmaceutical's January-September Profit Increases	23-10-25	MT
China Resources Boya Bio-pharmaceutical Group Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-25	CI
China Resources Double-Crane Pharmaceutical Co.,Ltd. agreed to acquire an 89.681% stake in Guizhou Tianan Pharmaceutical Company from Jiangxi Boya Pharmaceutical Investment Co., Ltd and China Resources Boya Bio-pharmaceutical Group Co.,Ltd for CNY 260 million	23-09-27	CI
China Resources Pharmaceutical Commercial Group Company Limited completed the acquisition of 75% stake in Guangdong Fuda Pharmaceutical Co., Ltd. from China Resources Boya Bio-pharmaceutical Group Co., Ltd..	23-09-24	CI
China Resources Pharmaceutical Commercial Group Company Limited agreed to acquire 75% stake in Guangdong Fuda Pharmaceutical Co., Ltd. from China Resources Boya Bio-pharmaceutical Group Co., Ltd. for approximately CNY 360 million.	23-08-29	CI
China Resources Pharmaceutical's Subsidiaries Log Increases in H1 Profits	23-08-25	MT
China Resources Boya's H1 Attributable Profit Jumps 16.9%	23-08-22	MT
China Resources Boya Bio-pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-21	CI
China Resources Boya Bio-pharmaceutical Group's Q1 Profit Rises	23-04-24	MT
China Resources Boya Bio-pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-24	CI
China Resources Boya Bio-pharmaceutical Group Co., Ltd. Approves Cash Dividend for 2022, Payable on 28 April 2023	23-04-17	CI
CR Boya Bio-pharmaceutical Estimates Higher Q1 Profit	23-04-11	MT
China Resources Boya Bio-Pharmaceutical Group Co., Ltd. Proposes Dividend for the Year 2022	23-03-27	CI
China Resources Boya Bio-pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-12	CI
CR Boya Bio-pharmaceutical's January-September Profit Rises	22-10-25	MT
China Resources Boya Bio-pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-24	CI
China Resources Boya Bio-pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-19	CI
China Resources Boya Bio-pharmaceutical Group Co., Ltd. announces the implementation of cash dividend for 2021, Payable on 13 May 2022	22-05-09	CI

Chart China Resources Boya Bio-pharmaceutical Group Co.,Ltd

Duration

Period

Chart China Resources Boya Bio-pharmaceutical Group Co.,Ltd

More charts

China Resources Boya Bio-pharmaceutical Group Co Ltd, formerly Boya Bio-pharmaceutical Group Co Ltd, is a China-based company principally engaged in the research, development, production and distribution of blood products. The Company's main products include human albumin, freeze-drying intravenous injection human immune globulin, human immune globulin, hepatitis B human immune globulin, hydrophobia human immune globulin, human fibrinogen, metformin hydrochloride, calcium dobesilate capsules, glimepiride and pioglitazone hydrochloride dispersible tablets, among others. The Company's blood products are mainly used in the treatment of tumor, liver diseases and diabetes, among others. The Company also provides diabetic pharmaceuticals and biochemical pharmaceuticals. The Company distributes its products mainly in domestic market.

Sector

Pharmaceuticals

Calendar

2024-08-28 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for China Resources Boya Bio-pharmaceutical Group Co.,Ltd

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

33.73 CNY

Average target price

34.45 CNY

Spread / Average Target

+2.12%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
CHINA RESOURCES BOYA BIO-PHARMACEUTICAL GROUP CO.,LTD	+0.15%	2.35B
CSL LIMITED	-3.15%	89.69B
SAMSUNG BIOLOGICS CO.,LTD.	+3.95%	41.34B
BIOGEN INC.	-10.51%	33.72B
UCB	+58.75%	26.11B
BIOMARIN PHARMACEUTICAL INC.	-20.09%	14.63B
INCYTE CORPORATION	-8.92%	12.84B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.46%	11.66B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.05%	11.52B
SWEDISH ORPHAN BIOVITRUM AB	+4.72%	8.92B

Biopharmaceuticals